Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
AssigneeUniversity of Miami
InventorsEckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
Life of this patent
Estimating the term…
Abstract
Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
Claims37
An isolated or recombinant nucleic acid comprising a polynucleotide sequence which encodes a TL1A fusion protein, the fusion protein comprising:
- (a) a first polypeptide comprising an extracellular domain of a human TL1A polypeptide or a fragment thereof that specifically binds to Tumor Necrosis Factor Receptor Superfamily, Member 25 (TNFRSF25), and (b) a second polypeptide comprising an immunoglobulin (Ig) polypeptide;
- or a complementary polynucleotide sequence thereof.
A composition comprising a human TL1A-Ig fusion protein, the fusion protein comprising (a) a first polypeptide comprising an extracellular domain of a human TL1A polypeptide or a fragment thereof that specifically binds to TNFRSF25;
- and (b) a second polypeptide comprising an Ig polypeptide.
Dependencies are inferred from the claim text.